ClinicalTrials.gg
CompletedNCT03449836Updated Sep 1, 2026

Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children

A Phase 3 interventional study of Streptococcus salivarius 24SMBc + Strept. oralis 89a and fluticasone + mometasone in Allergy, sponsored by Federico II University. Completed at 1 site in Italy. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Federico II University · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Hypersensitivity with a site in Italy — 1 open to participants now, 3 under way, none of them phase 3. Hypersensitivity · Italy.

Enrollment
23rd of 31
60 · median 237
Started
2018
with 6 others
Phase 3
10 of 43
none open now
Registered
22nd of 43
by date
Lead sponsor
7 of 43
Federico II University

Among the 43 studies in Hypersensitivity with a site in Italy, this one is the 23rd largest by enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2018, is one of 10 in phase 3, and was the 22nd registered.

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

1 of the 43 studies in Hypersensitivity with a site in Italy is open now. Recruiting first, the newest first:

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Hypersensitivity with a site in Italy, or all of them as a file.
02

Study summary

Allergic rhinoconjunctivitis is a pathology of the nasal and conjunctival mucosa induced by Immunoglobulin E (IgE) mediated inflammation following allergic exposure. This condition represents a global health problem that affects 5 to 20% of the population. As with all allergic diseases, its prevalence in pediatric age has increased over the last 30 years, as shown by the results of the international epidemiological study International Study of Asthma and Allergies in Childhood (ISAAC) which shows that the overall prevalence is 8.5 % in children aged 6-7 and 14.6% in children aged 13-14. In Italy, on average, the prevalence stands at 17.6% in the 6-7 year age range and 31.3% in the 13-14 age range, demonstrating a growing trend. The allergic rhinoconjunctivitis undiagnosed and / or not treated properly can negatively affect the school activities and in general the quality of life of children and their parents, as well as having important socio-economic repercussions in terms of medical expenses, school absences and days of work lost by parents. Furthermore, the lack of therapeutic intervention can lead to an increased risk of complications in the medium and long term. Recent advances in the understanding of the mechanisms underlying the inflammation of the airways have led to an improvement of the therapeutic strategies for the management of allergic rhinoconjunctivitis: the four cornerstones of the approach to this pathology promoted by the European Academy of Allergy and Clinical Immunology (EAACI) include allergen removal, patient education, pharmacotherapy and specific immunotherapy. However, there is discordant evidence to support their efficacy in reducing the symptomatology of allergic rhinoconjunctivitis, with the need to resort to the invasive surgical approach in several cases. Therefore, the use of probiotics, defined as "live micro-organisms which, when administered in adequate quantities, confer an advantage for the organism" can be useful. The mechanisms by which probiotics or their components, for example DNA, proteins and peptides, exert such beneficial effects concern the regulation of the immune system, the antagonist action against potentially pathogenic microorganisms and the quantitative and qualitative modulation of the intestinal microbiota. In fact, recent clinical studies have demonstrated the protective effect of infections of the high respiratory tract in adults and recurrent average otitis in pediatric age of the Streptococcus salivarius 24SMBc and Streptococcus oralis 89a strains administered through nasal spray. These well-characterized probiotics were safe, tolerated and able to positively modulate the composition of the respiratory epithelial microbiota and the function of the immune system.

03

Conditions studied

  • Allergy

Browse trials for

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children aged 6-12 months with allergic rhinoconjunctivitis

Exclusion criteria

Exclusion Criteria:

  • concomitant presence of chronic pathologies,
  • malformations of the respiratory tract and facial cranium,
  • tumors,
  • neurological diseases,
  • metabolic pathologies,
  • cystic fibrosis,
  • immunodeficiencies,
  • history of epistaxis,
  • alteration of coagulation factors,
  • history of apnea,
  • ciliary dyskinesia,
  • treatment with topical drugs nasal and / or oral anti-histaminics or antibiotic treatment in the 3 months prior to enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Streptococcus salivarius 24SMBc + Strept.oralis 89a

    spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a

    Combination Product: Streptococcus salivarius 24SMBc + Strept. oralis 89a

  • Active comparator
    fluticasone + mometasone

    spray with fluticasone and mometasone

    Combination Product: fluticasone + mometasone

  • Placebo comparator
    placebo

    spray with isotonic solution

    Other: placebo

Interventions

  • Combination productStreptococcus salivarius 24SMBc + Strept. oralis 89a

    nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a

  • Combination productfluticasone + mometasone

    Drug pages: Fluticasone · Mometasone Furoate

    nasal spray based on fluticasone + mometasone

  • Otherplacebo

    nasal spray based on isotonic solution

06

What researchers measure

Primary outcomes

  1. Total 5 Symptom Score (T5SS) from 0 to 15

    Symptoms evaluation was made by the Total 5 Symptoms Score (T5SS), which includes the symptoms of nasal discharge (rhinorrhea), nasal congestion, itchy nose, sneezing, and itchy eyes. All symptoms were graded from 0 (absent) to 3 (very troublesome),with total scores ranging from 0-15.

    Time frame: after 20 days of treatment

  2. Pittsburgh Sleep Quality Index (PSQI) score

    The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Consisting of 19 items, the PSQI measures several different aspects of sleep, offering seven component scores and one composite score. The component scores consist of subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the 7 component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.Traditionally, the items from the PSQI have been summed to create a total score to measure overall sleep quality.

    Time frame: after 20 days of treatment

Secondary outcomes

  1. Evaluation of nasal microbiota composition

    Evaluation of nasal microbiota composition with a nasal brushing and determination of phyla, class, order, family, genus

    Time frame: after 20 days of treatment

07

Study locations

1 site
  • University of Naples Federico II
    Naples, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Sep 2018, 6 months.

Of 42 phase 3 interventional studies under Hypersensitivity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Feb 28, 2018
StartActual
Mar 1, 2018
Primary completionActual
Sep 30, 2018
CompletionActual
Dec 31, 2018
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03449836
Responsible party
Roberto Berni Canani, MD, PhD (MD, PhD, Federico II University) — Principal investigator
First posted
Feb 28, 2018
Start date
Mar 1, 2018
Primary completion
Sep 30, 2018
Completion
Dec 31, 2018
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion